![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Lupin Pharm, Cornerstone Enter Agreement for Suprax
Lupin Pharm, Cornerstone Enter Agreement for Suprax
Lupin, the Mumbai-based pharma major, has announced that its wholly owned subsidiary, Lupin Pharmaceuticals (LPI), has entered into an alliance with Cornerstone BioPharma as a promotion partner in the U.S. for its Suprax (cefixime) anti-infective. Suprax was approved in 2004 and has been promoted by LPI's pediatric focused sales force. This partnership represents a significant expansion in the scope of physician coverage for Suprax in the $1.2 billion U.S. oral suspension anti-infective market.
PharmaBiz (http://www.pharmabiz.com/article/detnews.asp?articleid=25886)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct